Deregulation of splicing factors and breast cancer development

Journal of Molecular Cell Biology

Volumn 7, Issue 5, 2015, Pages 388-401

  Silipo, Marco ^a   Gautrey, Hannah ^a   Tyson Capper, Alison ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

alternative splicing; breast cancer; RNA binding proteins; splicing factors

Indexed keywords

APC PROTEIN; CYCLIN D1; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; HUR PROTEIN; POLYPYRIMIDINE TRACT BINDING PROTEIN; PROLINE GLUTAMIC ACID AND LEUCINE RICH PROTEIN 1; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 6; PROTEIN C MYB; PROTEIN DAM1; PROTEIN FOX2; PROTEIN HNRNPA; PROTEIN HNRNPB; PROTEIN SAM68; PROTEIN SPF45; PROTEIN SRSF1; PROTEIN SRSF10; PROTEIN SRSF2; PROTEIN SRSF3; PROTEIN SRSF5; PROTEIN SRSF6; RAC1 PROTEIN; RNA BINDING MOTIF PROTEIN 5; RNA BINDING PROTEIN; SERINE ARGININE RICH PROTEIN; SPLICING FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; Y BOX BINDING PROTEIN 1;

ALTERNATIVE RNA SPLICING; APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INHIBITION; HUMAN; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA PROCESSING; RNA TRANSCRIPTION; SPLICEOSOME; TUMOR VASCULARIZATION; ANIMAL; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; RNA SPLICING;

ALTERNATIVE SPLICING; ANIMALS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RNA SPLICING; RNA-BINDING PROTEINS;

EID: 84943524223     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjv027     Document Type: Review

References (156)

1. Adams, J., Carder, P.J., Downey, S., et al. (2000). Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 60, 2898-2905.
2. Amin, E.M., Oltean, S., Hua, J., et al. (2011). WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 20, 768-780.
3. Anczukow, O., Rosenberg, A.Z., Akerman, M., et al. (2012). The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat. Struct. Mol. Biol. 19, 220-228.
4. Anko, M.L., Muller-McNicoll, M., Brandl, H., et al. (2012). The RNA-binding landscapes oftwo SRproteins reveal unique functions and binding todiverse RNA classes. Genome Biol. 13, R17.
5. Auboeuf, D., Batsche, E., Dutertre, M., et al. (2007). Coregulators: transducing signal from transcription to alternative splicing. Trends Endocrinol. Metab. 18, 122-129.
6. Baraniak, A.P., Chen, J.R., and Garcia-Blanco, M.A. (2006). Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice. Mol. Cell. Biol. 26, 1209-1222.
7. Ben-Hur, V., Denichenko, P., Siegfried, Z., et al. (2013). S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep. 3, 103-115.
8. Bergmann, S., Royer-Pokora, B., Fietze, E., et al. (2005). YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 65, 4078-4087.
9. Best, A., James, K., Dalgliesh, C., et al. (2014). Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons. Nat. Commun. 5, 4760.
10. Boise, L.H., Gonzalez-Garcia, M., Postema, C.E., et al. (1993). bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597-608.
11. Bonomi, S., di Matteo, A., Buratti, E., et al. (2013). HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition. Nucleic Acids Res. 41, 8665-8679.
12. Brinkman, B.M. (2004). Splice variantsas cancer biomarkers. Clin. Biochem. 37, 584-594.
13. Caestecker, K.W., and Van de Walle, G.R. (2013). The role of BRCA1 in DNA double-strand repair: past and present. Exp. Cell Res. 319, 575-587.
14. Cartegni, L., Chew, S.L., and Krainer, A.R. (2002). Listeningto silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3, 285-298.
15. Catena, R., Muniz-Medina, V., Moralejo, B., et al. (2007). Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis. Int. J. Cancer 120, 2096-2109.
16. ′s multifunctional regulatory roles. RNA 16, 1449-1462.
17. Chen, M., and Manley, J.L. (2009).Mechanismsofalternativesplicing regulation: insights from molecular and genomics approaches. Nat. Rev. Mol. Cell Biol. 10, 741-754.
18. Cheng, C., and Sharp, P.A. (2006). Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol. Cell. Biol. 26, 362-370.
19. Cheng, D., Cote, J., Shaaban, S., et al. (2007). The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Mol. Cell 25, 71-83.
20. ′ splice site consensus sequences and U6 snRNA during the second catalytic step of pre-mRNA splicing. RNA 7, 1845-1854.
21. Corsini, L., Bonnal, S., Basquin, J., et al. (2007). U2AF-homology motif interactions are required for alternative splicing regulation by SPF45. Nat. Struct. Mol. Biol. 14, 620-629.
22. Cote, J., Dupuis, S., and Wu, J.Y. (2001). Polypyrimidine track-binding protein binding downstream of caspase-2 alternative exon 9 represses its inclusion. J. Biol. Chem. 276, 8535-8543.
23. Cunha, S., Lin, Y.C., Goossen, E.A., et al. (2014). The RON receptor tyrosine kinase promotes metastasisby triggering MBD4-dependent DNA methylation reprogramming. Cell Rep. 6, 141-154.
24. Das, S., Anczukow, O., Akerman, M., et al. (2012). Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep. 1, 110-117.
25. David, C.J., and Manley, J.L. (2010). Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24, 2343-2364.
26. David, C.J., Chen, M., Assanah, M., et al. (2010). HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463, 364-368.
27. David, C.J., Boyne, A.R., Millhouse, S.R., et al. (2011). The RNA polymerase II C-terminal domain promotes splicing activation through recruitment of a U2AF65-Prp19 complex. Genes Dev. 25, 972-983.
28. Davies, A.H., Barrett, I., Pambid, M.R., et al. (2011). YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification. Oncogene 30, 3649-3660.
29. De Craene, B., and Berx, G. (2013). Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13, 97-110.
30. Denkert, C., Weichert, W., Winzer, K.J., et al. (2004). Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin. Cancer Res. 10, 5580-5586.
31. Dowhan, D.H., Hong, E.P., Auboeuf, D., et al. (2005). Steroid hormone receptor coactivation and alternative RNA splicingbyU2AF65-related proteins CAPERa and CAPERb. Mol. Cell 17, 429-439.
32. Dowhan, D.H., Harrison, M.J., Eriksson, N.A., et al. (2012). Protein arginine methyltransferase 6-dependent gene expression and splicing: association with breast cancer outcomes. Endocr. Relat. Cancer 19, 509-526.
33. Drabsch, Y., Robert, R.G., andGonda, T.J. (2010).MYB suppressesdifferentiation and apoptosis of human breast cancer cells. Breast Cancer Res. 12, R55.
34. Dutertre, M., Vagner, S., and Auboeuf, D. (2010). Alternative splicing and breast cancer. RNA Biol. 7, 403-411.
35. Evdokimova, V., Tognon, C., Ng, T., et al. (2009). Translational activation ofsnail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 15, 402-415.
36. Filipits, M., Malayeri, R., Suchomel, R.W., et al. (1999). Expression of the multi-drug resistance protein (MRP1) in breast cancer. Anticancer Res. 19, 5043-5049.
37. Fu, X.D. (1995). The superfamily of arginine/serine-rich splicing factors. RNA 1, 663-680.
38. ′ splice site selection. Proc. Natl Acad. Sci. USA 89, 11224-11228.
39. Fujii, T., Kawahara, A., Basaki, Y., et al. (2008). Expression of HER2 and estrogen receptor a depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res. 68, 1504-1512.
40. Fumagalli, S., Totty, N.F., Hsuan, J.J., et al. (1994). A target for Src in mitosis. Nature 368, 871-874.
41. Fushimi, K., Ray, P., Kar, A., et al. (2008). Up-regulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5. Proc. Natl Acad. Sci. USA 105, 15708-15713.
42. Gasco, M., Shami, S., and Crook, T. (2002). The p53 pathway in breast cancer. Breast Cancer Res. 4, 70-76.
43. Gautrey, H.L., and Tyson-Capper, A.J. (2012). Regulation of Mcl-1 by SRSF1 and SRSF5 in cancer cells. PLoS One 7, e51497.
44. Ge, K., DuHadaway, J., Du, W., et al. (1999).Mechanismforeliminationofatumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc. Natl Acad. Sci. USA 96, 9689-9694.
45. Ge, K., Duhadaway, J., Sakamuro, D., et al. (2000). Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int. J. Cancer 85, 376-383.
46. Ghigna, C., Giordano, S., Shen, H., et al. (2005). Cell motilityiscontrolled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol. Cell 20, 881-890.
47. Ghigna, C., Valacca, C., and Biamonti, G. (2008). Alternative splicing and tumor progression. Curr. Genomics 9, 556-570.
48. Golan-Gerstl, R., Cohen, M., Shilo, A., et al. (2011). Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glio-blastoma. Cancer Res. 71, 4464-4472.
49. Goncalves, V., Theisen, P., Antunes, O., et al. (2009).Amissense mutationin the APC tumor suppressor gene disruptsan ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14. Mutat. Res. 662, 33-36.
50. Grosso, A.R., Martins, S., and Carmo-Fonseca, M. (2008). The emerging role of splicing factors in cancer. EMBO Rep. 9, 1087-1093.
51. Groth, C., and Lardelli, M. (2002). The structure and function of vertebrate fibro-blast growth factor receptor 1. Int. J. Dev. Biol. 46, 393-400.
52. Han, N., Li, W., and Zhang, M. (2013). The function of the RNA-binding protein hnRNP in cancer metastasis. J. Cancer Res. Ther. 9(Suppl), S129-S134.
53. He, X., Ee, P.L., Coon, J.S., et al. (2004). Alternative splicing of the multidrug resistance protein1/ATPbinding cassette transporter subfamily geneinovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin. Cancer Res. 10, 4652-4660.
54. He, Y., Brown, M.A., and Rothnagel, J.A., et al. (2005). Roles of heterogeneous nuclear ribonucleoproteins A and B in cell proliferation. J. Cell Sci. 118, 3173-3183.
55. He, X., Arslan, A.D., Ho, T.T., et al. (2014). Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties. Oncogenesis 3, e84.
56. Ho, K.Y., Kalle, W.H., Lo, T.H., et al. (1999). Reduced expression of APC and DCC gene protein in breast cancer. Histopathology 35, 249-256.
57. Huang, C.S., Shen, C.Y., Wang, H.W., et al. (2007). Increase dexpression of SRp40 affecting CD44 splicing isassociated with the clinical outcome oflymph node metastasis in human breast cancer. Clin. Chim. Acta 384, 69-74.
58. Hunter, D.J., Kraft, P., Jacobs, K.B., et al. (2007). A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmeno-pausal breast cancer. Nat. Genet. 39, 870-874.
59. Izquierdo, J.M. (2008). Huantigen R (HuR) functions asanalternative pre-mRNA splicing regulator of Fas apoptosis-promoting receptor on exon definition. J. Biol. Chem. 283, 19077-19084.
60. Izquierdo, J.M., Majos, N., Bonnal, S., et al. (2005). Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol. Cell 19, 475-484.
61. Jackson, C., Browell, D., Gautrey, H., et al. (2013). Clinical significance of HER-2 splice variants in breast cancer progression and drug resistance. Int. J. Cell Biol. 2013, 973584.
62. Janz, M., Harbeck, N., Dettmar, P., et al. (2002). Y-box factor YB-1 predicts drug resistanceandpatientoutcomeinbreastcancer independentofclinicallyrele-vant tumor biologic factors HER2, uPA and PAI-1. Int. J. Cancer 97, 278-282.
63. Jia, R., Li, C., McCoy, J.P., et al. (2010). SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance. Int. J. Biol. Sci. 6, 806-826.
64. Jiang, Z.H., Zhang, W.J., Rao, Y., et al. (1998). Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. Proc. Natl Acad. Sci. USA 95, 9155-9160.
65. Jo, O.D., Martin, J., Bernath, A., et al. (2008). Heterogeneous nuclear ribonucleo-proteinA1 regulates cyclin D1and c-myc internal ribosome entry site function through Akt signaling. J. Biol. Chem. 283, 23274-23287.
66. Karni, R., deStanchina, E., Lowe, S.W., et al. (2007). The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 14, 185-193.
67. Kim, C.J., Nishi, K., Isono, T., et al. (2009). Cyclin D1b variant promotes cell inva-siveness independent of binding to CDK4in human bladder cancer cells. Mol. Carcinog. 48, 953-964.
68. Kim, N.H., Kim, S.N., Seo, D.W., et al. (2013). PRMT6 overexpression upregulates TSP-1 and downregulates MMPs: its implication in motility and invasion. Biochem. Biophys. Res. Commun. 432, 60-65.
69. Klinck, R., Bramard, A., Inkel, L., et al. (2008). Multiple alternative splicing markers for ovarian cancer. Cancer Res. 68, 657-663.
70. Knopfova, L., Benes, P., Pekarcikova, L., et al. (2012). c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: implications for matrix-dependent breast cancer cell invasion and metastasis. Mol. Cancer 11, 15.
71. Konig, J., Zarnack, K., Rot, G., et al. (2010). iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. Nat. Struct. Mol. Biol. 17, 909-915.
72. Konig, J., Zarnack, K., Rot, G., et al. (2011). iCLIP-transcriptome-wide mapping of protein-RNA interactions with individual nucleotide resolution. J. Vis. Exp. (50), 2638.
73. Kovalev, A.A., Tsvetaeva, D.A., and Grudinskaja, T.V. (2013). Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primaryand acquired multipledrug resistanceinpatients withearlyand meta-static breast cancer. Exp. Oncol. 35, 287-290.
74. ′ splice site selection by activating proximal sites. Cell 62, 35-42.
75. Kumar, A., Baker, S.J., Lee, C.M., et al. (2003). Molecularmechanismsassociated with the regulation of apoptosis by the two alternatively spliced products of c-Myb. Mol. Cell. Biol. 23, 6631-6645.
76. Kuo, P.C., Tsao, Y.P., Chang, H.W., et al. (2009). Breast cancer amplified sequence 2, a novel negative regulator of the p53 tumor suppressor. Cancer Res. 69, 8877-8885.
77. Lal, S., Allan, A., Markovic, D., et al. (2013). Estrogen alters the splicing of type 1 corticotropin-releasing hormone receptorin breast cancer cells. Sci. Signal. 6, ra53.
78. Lapuk, A., Marr, H., Jakkula, L., et al. (2010). Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol. Cancer Res. 8, 961-974.
79. Lee, S., Ha, S., Chung, M., et al. (2002). Mouse DAM1 regulates pro-apoptotic activity of BLK in mammary epithelial cells. Cancer Lett. 188, 121-126.
80. Li, B.D., Liu, L., Dawson, M., et al. (1997). Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 79, 2385-2390.
81. Li, S., Xu, H., Ding, H., et al. (2009). Identificationof anaptamer targeting hnRNP A1 by tissue slide-based SELEX. J. Pathol. 218, 327-336.
82. Li, X., and Manley, J.L. (2005). Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell 122, 365-378.
83. Lin, J.H., and Yamazaki, M. (2003). Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42, 59-98.
84. Liu, Y., Conaway, L., Rutherford Bethard, J., et al. (2013). Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion. Nucleic Acids Res. 41, 4949-4962.
85. Lixia, M., Zhijian, C., Chao, S., et al. (2007). Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line. J. Biochem. Mol. Biol. 40, 15-21.
86. Luqmani, Y.A., Mortimer, C., Yiangou, C., et al. (1995). Expression of 2 variant forms of fibroblast growth factor receptor 1 in human breast. Int. J. Cancer 64, 274-279.
87. Maass, N., Rosel, F., Schem, C., et al. (2002). Amplification of the BCAS2 gene at chromosome 1p13.3-21 in human primary breast cancer. Cancer Lett. 185, 219-223.
88. Mandal, M., Vadlamudi, R., Nguyen, D., et al. (2001). Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J. Biol. Chem. 276, 9699-9704.
89. Manley, J.L., and Tacke, R. (1996). SR proteins and splicing control. Genes Dev. 10, 1569-1579.
90. Mann, M., Zou, Y., Chen, Y., et al. (2014). PELP1 oncogenic functions involve alternative splicing via PRMT6. Mol. Oncol. 8, 389-400.
91. Matter, N., Herrlich, P., and Konig, H. (2002). Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420, 691-695.
92. Mauger, D.M., Lin, C., and Garcia-Blanco, M.A. (2008). hnRNP H and hnRNP F complex with Fox2 to silence fibroblast growth factor receptor 2 exon IIIc. Mol. Cell. Biol. 28, 5403-5419.
93. Mayeda, A., Helfman, D.M., and Krainer, A.R. (1993). Modulation of exon skipping and inclusion by heterogeneous nuclear ribonucleoprotein A1 and pre-mRNA splicing factor SF2/ASF. Mol. Cell. Biol. 13, 2993-3001.
94. McManus, C.J., and Graveley, B.R. (2011). RNA structure and the mechanisms of alternative splicing. Curr. Opin. Genet. Dev. 21, 373-379.
95. Moffa, A.B., and Ethier, S.P. (2007). Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J. Cell. Physiol. 210, 720-731.
96. Mylona, E., Melissaris, S., Giannopoulou, I., et al. (2014). Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse. Eur. J. Surg. Oncol. 40, 289-296.
97. Nagasaki, K., Maass, N., Manabe, T., et al. (1999). Identification of anovel gene, DAM1, amplified at chromosome 1p13.3-21 region in human breast cancer cell lines. Cancer Lett. 140, 219-226.
98. Naor, D., Sionov, R.V., and Ish-Shalom, D.(1997).CD44: structure, function, and association with the malignant process. Adv. Cancer Res. 71, 241-319.
99. Nooter, K., Brutel de la Riviere, G., Look, M.P., et al. (1997). The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br. J. Cancer 76, 486-493.
100. Norris, J.D., Fan, D., Sherk, A., et al. (2002).A negative coregulator for the human ER. Mol. Endocrinol. 16, 459-468.
101. O'Rourke, J.P., and Ness, S.A. (2008). AlternativeRNA splicing produces multiple forms of c-Myb with unique transcriptional activities. Mol. Cell. Biol. 28, 2091-2101.
102. Oh, H., Lee, E., Jang, H.N., et al. (2013). hnRNP A1 contacts exon 5 to promote exon 6 inclusion of apoptotic Fas gene. Apoptosis 18, 825-835.
103. Olshavsky, N.A., Comstock, C.E., Schiewer, M.J., et al. (2010). Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res. 70, 3975-3984.
104. Olsson, E., Honeth, G., Bendahl, P.O., et al.(2011). CD44 isoforms are heteroge-neously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer 11, 418.
105. Orban, T.I., and Olah, E. (2003). Emerging roles of BRCA1 alternative splicing. Mol. Pathol. 56, 191-197.
106. Ortiz-Martinez, F., Perez-Balaguer, A., Ciprian, D., et al. (2014). Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. Hum. Pathol. 45, 504-512.
107. Paronetto, M.P., Achsel, T., Massiello, A., et al. (2007). The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J. Cell Biol. 176, 929-939.
108. Paronetto, M.P., Cappellari, M., Busa, R., et al. (2010). Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res. 70, 229-239.
109. Patry, C., Bouchard, L., Labrecque, P., et al. (2003). Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res. 63, 7679-7688.
110. Phalke, S., Mzoughi, S., Bezzi, M., et al. (2012). p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6. Nucleic Acids Res. 40, 9534-9542.
111. Pind, M.T., and Watson, P.H. (2003). SR protein expression and CD44 splicing pattern in human breast tumours. Breast Cancer Res. Treat. 79, 75-82.
112. Pollard, A.J., Sparey, C., Robson, S.C., et al. (2000). Spatio-temporal expression of the trans-acting splicing factors SF2/ASF and heterogeneous ribonuclear proteins A1/A1Binthe myometriumofthe pregnant human uterus: amolecu-lar mechanism for regulating regional protein isoform expression in vivo. J. Clin. Endocrinol. Metab. 85, 1928-1936.
113. Qi, C., Zhu, Y.T., Chang, J., et al. (2005). Potentiation of estrogen receptor tran-scriptional activity by breast cancer amplified sequence 2. Biochem. Biophys. Res. Commun. 328, 393-398.
114. Quintana, A.M., Liu, F., O'Rourke, J.P., et al. (2011). Identification and regulation of c-Myb target genes in MCF-7 cells. BMC Cancer 11, 30.
115. Raponi, M., Smith, L.D., Silipo, M., et al. (2014). BRCA1 exon 11 a model of long exon splicing regulation. RNA Biol. 11, 351-359.
116. Rintala-Maki, N.D., Goard, C.A., Langdon, C.E., et al. (2007). Expression of RBM5-related factors in primary breast tissue. J. Cell. Biochem. 100, 1440-1458.
117. Roy, P.G., and Thompson, A.M. (2006). Cyclin D1 and breast cancer. Breast 15, 718-727.
118. Rubin, I., and Yarden, Y.(2001). The basic biologyofHER2. Ann. Oncol. 12(Suppl 1), S3-S8.
119. Rubinstein, D.B., Stortchevoi, A., Boosalis, M., et al. (2002). Overexpression of DNA-binding protein B gene product in breast cancer as detected by in vitro-generated combinatorial human immunoglobulin libraries. Cancer Res. 62, 4985-4991.
120. Sampath, J., Long, P.R., Shepard, R.L., et al. (2003). Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. Am. J. Pathol. 163, 1781-1790.
121. Scheper, G.C., Parra, J.L., Wilson, M., et al. (2003). The N and C termini of the splice variants of the human mitogen-activated protein kinase-interacting kinase Mnk2 determine activity and localization. Mol. Cell. Biol. 23, 5692-5705.
122. Schnelzer, A., Prechtel, D., Knaus, U., et al. (2000). Rac1inhuman breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19, 3013-3020.
123. Shi, S.T., Yu, G.Y., and Lai, M.M. (2003). Multiple type A/B heterogeneous nuclear ribonucleoproteins (hnRNPs) can replace hnRNP A1 in mouse hepatitis virus RNA synthesis. J. Virol. 77, 10584-10593.
124. Shi, J., Hu, Z., Pabon, K., et al. (2008). Caffeine regulates alternative splicing in a subsetofcancer-associatedgenes:aroleforSC35.Mol.Cell.Biol.28, 883-895.
125. Shibata, T., Kan, H., Murakami, Y., et al. (2013). Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells. Mol. Cancer Ther. 12, 737-746.
126. Shimoni-Sebag, A., Lebenthal-Loinger, I., Zender, L., et al. (2013). RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation. Carcinogenesis 34, 2498-2504.
127. Slamon, D.J., Clark, G.M., Wong, S.G., et al. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
128. Song, L., Wang, L., Li, Y., et al. (2010). Sam68 up-regulation correlates with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells. J. Pathol. 222, 227-237.
129. Soni, A., Akcakanat, A., Singh, G., et al. (2008). eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol. Cancer Ther. 7, 1782-1788.
130. Srebrow, A., and Kornblihtt, A.R. (2006). The connection between splicing and cancer. J. Cell Sci. 119, 2635-2641.
131. Stickeler, E., Kittrell, F., Medina, D., et al. (1999). Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 18, 3574-3582.
132. Swamynathan, S.K., Varma, B.R., Weber, K.T., et al. (2002). Targeted disruption of one allele of the Y-box protein gene, Chk-YB-1b, in DT40 cells results in major defects in cell cycle. Biochem. Biophys. Res. Commun. 296, 451-457.
133. Tammaro, C., Raponi, M., Wilson, D.I., et al. (2012). BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer. Biochem. Soc. Trans. 40, 768-772.
134. Tang, Y., Horikawa, I., Ajiro, M., et al. (2013). Downregulation of splicing factor SRSF3 induces p53b, an alternatively spliced isoform of p53 that promotes cellular senescence. Oncogene 32, 2792-2798.
135. Tang, F., Li, W., Chen, Y., et al. (2014). Downregulation of hnRNP K by RNAi inhibits growth of human lung carcinoma cells. Oncol. Lett. 7, 1073-1077.
136. Thorner, A.R., Parker, J.S., Hoadley, K.A., et al. (2010). Potential tumor suppressor rolefor thec-Myb oncogeneinluminalbreast cancer. PLoS One 5, e13073.
137. Twyffels, L., Gueydan, C., and Kruys, V.(2011). Shuttling SRproteins: more than splicing factors. FEBS J. 278, 3246-3255.
138. Vadlamudi, R.K., Wang, R.A., Mazumdar, A., et al. (2001). Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor a. J. Biol. Chem. 276, 38272-38279.
139. Valacca, C., Bonomi, S., Buratti, E., et al. (2010). Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J. Cell Biol. 191, 87-99.
140. Venables, J.P., Brosseau, J.P., Gadea, G., et al. (2013). RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Mol. Cell. Biol. 33, 396-405.
141. Venables, J.P., Klinck, R., Bramard, A., et al. (2008a). Identification of alternative splicing markers for breast cancer. Cancer Res. 68, 9525-9531.
142. Venables, J.P., Klinck, R., Koh, C., et al. (2009). Cancer-associated regulation of alternative splicing. Nat. Struct. Mol. Biol. 16, 670-676.
143. Venables, J.P., Koh, C.S., Froehlich, U., et al. (2008b). Multiple and specific mRNA processing targets for the major human hnRNP proteins. Mol. Cell. Biol. 28, 6033-6043.
144. Watermann, D.O., Tang, Y., Zur Hausen, A., et al. (2006). Splicing factor Tra2-b1 isspecifically inducedinbreast cancerandregulatesalternativesplicingofthe CD44 gene. Cancer Res. 66, 4774-4780.
145. Wurth, L. (2012). Versatility of RNA-binding proteins in cancer. Comp. Funct. Genomics 2012, 178525.
146. Xiao, R., Sun, Y., Ding, J.H., et al. (2007). Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis. Mol. Cell. Biol. 27, 5393-5402.
147. Yamnik, R.L., Digilova, A., Davis, D.C., et al. (2009). S6 kinase 1 regulates estrogen receptor a in control of breast cancer cell proliferation. J. Biol. Chem. 284, 6361-6369.
148. Yang, P., Du, C.W., Kwan, M., et al. (2013). The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis. Sci. Rep. 3, 2246.
149. Yeo, G.W., Coufal, N.G., Liang, T.Y., et al. (2009). An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells. Nat. Struct. Mol. Biol. 16, 130-137.
150. Zhang, N., Kaur, R., Lu, X., et al. (2005). The Pso4 mRNA splicing and DNA repair complex interacts with WRN for processing of DNA interstrand cross-links. J. Biol. Chem. 280, 40559-40567.
151. Zhang, C., Zhang, Z., Castle, J., et al. (2008).Definingthe regulatory networkofthe tissue-specific splicing factors Fox-1 and Fox-2. Genes Dev. 22, 2550-2563.
152. Zhou, J., Allred, D.C., Avis, I., et al. (2001).Differential expressionofthe early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res. Treat. 66, 217-224.
153. Zhou, R., Shanas, R., Nelson, M.A., et al. (2010). Increased expressionofthe heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. Int. J. Cancer 126, 395-404.
154. Zhou, C., Licciulli, S., Avila, J.L., et al. (2013). The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis. Oncogene 32, 903-909.
155. Zhu, X., Asa, S.L., and Ezzat, S. (2009). Histone-acetylated control of fibroblast growth factor receptor 2 intron 2 polymorphisms and isoform splicing in breast cancer. Mol. Endocrinol. 23, 1397-1405.
156. Zuo, P., and Manley, J.L. (1993). Functional domains ofthe human splicing factor ASF/SF2. EMBO J. 12, 4727-4737.